23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA), Metabolic Endocrine Education Foundation (MEEF) and will be held from Dec 03 - 06, 2025 at Hilton Los Angeles/Universal City, Universal City, California, United States of America.

Program Description:
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 23rd year, is a premier multidisciplinary CME conference, recognized as the leading global forum on CardioRenalMetabolism- diabetes, obesity, lipids, cardiovascular, kidney, and liver diseases. The Congress uniquely integrates basic science with clinical practice under its guiding theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science. Today.

Participants are able to earn up to TBD CME & ABIM-MOC credits.

The WCIRDC program offers a unique convergence of basic, translational and clinical science. For over two decades, it has brought together physicians, clinicians, researchers, and other healthcare professionals from around the world to participate in an exclusive program that seamlessly bridges the latest discoveries from bench to bedside and back again.

Frequently described with the phrase, “I heard it first at WCIRDC,” the Congress provides an unparalleled opportunity to engage directly with distinguished global faculty in an intimate setting. This dynamic exchange propels understanding of metabolic diseases and advances the exploration of emerging therapeutic approaches.

Since the seminal work of Dr. Gerald Reaven, which crystallized the interplay among insulin resistance, diabetes, obesity, and cardiovascular disease, the scope of the Congress has significantly expanded. It now extends to the kidney, liver, brain, bone, cancer, and beyond.

The program encompasses key areas such as dyslipidemia, atherosclerosis, hypertension, hypercoagulation, and inflammation, with a strong focus on the intricate connections across Diabetes–Cardio–Renal and Metabolic Diseases.

In addition, the agenda highlights the latest updates on pharmaceutical interventions, including incretins (GLP-1 RAs and dual agonists), SGLT2i and SGLT2/1i, PCSK9i, nsMRA, anticoagulants and antihypertension.. The goal is to foster a comprehensive understanding of cutting-edge pathophysiology, novel therapeutic approaches, and the development of integrated clinical management strategies in metabolic disorders and comorbidities.

To bridge the gap between research and clinical practice, each session will be followed by live Q&A and panel discussions to explore the clinical implications of new findings. Enhanced opportunities for interaction with faculty and peers will also be built into the program through extended breaks and social events.

The Congress showcases cutting-edge abstracts from both emerging investigators and world-renowned leaders. The highest-ranked abstracts will be selected for oral presentation, highlighting innovative contributions to the field.

This year’s recipient of the Gerald Reaven Distinguished Leader Award is Dr. Tracey McLaughlin- a Stanford Professor. She will deliver the keynote lecture.- Adipocyte Dysfunction and the Metabolic Heterogeneity of Obesity. In addition, Clinical Workshops and Meet-the-Experts sessions will provide small-group learning and intimate, face-to-face engagement with some of the most respected leaders in metabolic disease research and practice.

Program Objectives:
The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, CVD and CKD, focusing on insulin resistance, incretins, the gut, the brain, the kidney and the heart. The goal is to understand pathophysiology and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

• Describe the relationship between insulin resistance, obesity, diabetes, kidney disease, and heart disease
• Discuss evolving concepts, diagnosis and therapeutic interventions for MASLD-(NAFLD) and MASH(NASH)
• Discuss pharmacologic strategies for obesity management and prevention of obesity complications
• Implement best practices for the prevention and management of CKD, HF, and ASCVD
• Understand the contemporary role of SGLT2 inhibitors in HF & CKD with and without diabetes
• Describe the benefits of GLP1-RA–based therapy alone and in combination with other incretin agents in patients with ASCVD or at risk of ASCVD events
• Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD
• Discuss and understand the role of GLP1-RAs based therapy in HFpEF
• Evaluate the impact on the clinical practice of new CVOTs in patients with obesity, diabetes and cardiometabolic diseases
• Design therapeutic regimens for patients with multiple cardiometabolic and renal disorders that capitalize on agents with broad effects across the spectrum of these comorbidities
• Utilize technology and digital health to enhance the effectiveness of therapeutics
• Understand the emerging role of artificial intelligence in health care, including diagnosis, designing treatment plans, and education
• Recognize the important role of adrenal hormones specifically Aldosterone and Cortisol in the development of DM, HTN, heart and kidney diseases